We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. The third stock on our list is BridgeBio Pharma, Inc.
TheFly reported on January 8 that Truist raised its price target on BBIO to $86 from $80 while maintaining a Buy rating. The firm updated its model but noted in a research note that its fundamental views remain unchanged from 2025.
In keeping with this positive view, on January 12, BridgeBio Pharma, Inc. (NASDAQ:BBIO) gave a significant operational update at the 44th Annual J.P. Morgan Healthcare Conference. For Attruby, the firm announced preliminary unaudited revenues of $146.0 million for the fourth quarter of 2025, totaling $362.4 million in product revenue for the full year of 2025. This accomplishment amply illustrates the rapid market adoption of Attruby as a first-choice treatment for newly diagnosed ATTR-CM patients, with over 6,000 unique prescriptions written by the end of 2025.
BridgeBio Pharma, Inc. develops therapies for genetic diseases and cancers, supporting its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT), which advances precision cancer treatments targeting key oncogenes like RAS and PI3K into clinical trials.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Hedge Fund Resource Center